公开(公告)号：US20190203192A1

公开(公告)日：2019-07-04

申请号：US15859500

申请日：2017-12-30

Applicant: Development Center for Biotechnology

Inventor： Jei-Hwa YU ,  Iok-U FONG ,  Su-Yi HSU ,  Chih-Yung HU ,  Chia-Cheng WU

IPC: C12N9/64 ,  C07K16/22 ,  C07K14/575 ,  C07K16/28 ,  A61P25/00 ,  A61P35/00 ,  A61P37/02 ,  A61P31/00

CPC classification number: C12N9/6445 ,  A61K39/395 ,  A61K2039/505 ,  A61P25/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/5759 ,  C07K16/22 ,  C07K16/2803 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

Abstract: An antibody prodrug capable of being selectively activated in a central nervous system (CNS) by protease KLK6 includes an antibody for treating a disease or disorder in the CNS; a KLK6 cleavable peptide fused to an N-terminus of a heavy chain and/or a light chain of the antibody; and a blocker fused to an N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, inflammatory disease, autoimmune disease, infectious disease, or neuron degeneration disease.